Gyre Therapeutics, Inc.

Gyre Therapeutics Inc's next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, Gyre Therapeutics Inc has 106.03M shares outstanding.

As of June 30, 2026, Gyre Therapeutics Inc maintains a current ratio of 4.26, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Gyre Therapeutics Inc posted a negative return on equity (ROE) of -18.47, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.89, reflecting losses generated across the asset base. The company generates approximately 222,331.79 in revenue per employee across its workforce of 470.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.67 indicates how many times Gyre Therapeutics Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Gyre Therapeutics Inc recorded 3.02M in income tax expense. The company reported a pretax loss of -14.10M and -15.24M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Gyre Therapeutics Inc generated 104.50M in revenue and converted that into -15.24M in net income, yielding earnings per share of -0.18. EBITDA reached -11.86M, while operating income came in at -11.92M.

As of June 30, 2026, Gyre Therapeutics Inc holds 65.47M in cash and equivalents against 2.99M in total debt, resulting in a net debt position of -37.89M. Total book value stands at 94.47M, with working capital of 81.76M providing operational flexibility.

Gyre Therapeutics Inc produced -4.32M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.94M in capital expenditures, free cash flow totaled -6.26M - equivalent to -0.07 per share.

Over the twelve months ended June 30, 2026, Gyre Therapeutics Inc posted a gross margin of 94.30, reflecting its pricing power and cost economics. The operating margin of -11.41 and net profit margin of -14.58 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 4.65 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Gyre Therapeutics Inc's most recent stock split took place on October 31, 2023 with a 15:1 split ratio.